Susquehanna International Group’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Susquehanna International Group’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,000	Closed	-$6K	–	10638
2018 Q4	$6K	Buy	+10,000	New	+$10.4K	﹤0.01%	8784
2018 Q2	–	Sell	-27,200	Closed	-$39K	–	11061
2018 Q1	$39K	Sell	27,200 -45,100	-62%	-$94.2K	﹤0.01%	9027
2017 Q4	$163K	Sell	72,300 -30,900	-30%	-$78.2K	﹤0.01%	8437
2017 Q3	$351K	Buy	103,200 +42,000	+69%	+$141K	﹤0.01%	7123
2017 Q2	$217K	Buy	+61,200	New	+$202K	﹤0.01%	8151
2015 Q4	–	Sell	-30,700	Closed	-$119K	–	10644
2015 Q3	$119K	Buy	30,700 +100	+0.3%	+$459	﹤0.01%	9058
2015 Q2	$141K	Buy	+30,600	New	+$293K	﹤0.01%	9523

Susquehanna International Group's AST Position: Q4 2018 in Review

Susquehanna International Group sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2018, closing a stake of 60,989 shares — an estimated $63.3K sold.

Susquehanna International Group first reported a position in AST in Q1 2015 and held it in 11 quarters. The position peaked at $368K in Q4 2017. 46 funds tracked by Wall St. Rank hold AST as of Q4 2018.

Susquehanna International Group reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2018 after selling out during the quarter.
Susquehanna International Group sold 60,989 Asterias Biotherapeutics Inc. Series A shares in Q4 2018, an estimated $63.3K.
Susquehanna International Group first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2015 and held it in 11 quarters.
Susquehanna International Group's Asterias Biotherapeutics Inc. Series A position peaked at $368K in Q4 2017.
46 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2018.

Based on Susquehanna International Group's 13F filing for Q4 2018, filed 14 Feb 2019.